CZ293787B6 - pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii - Google Patents

pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii Download PDF

Info

Publication number
CZ293787B6
CZ293787B6 CZ20014653A CZ20014653A CZ293787B6 CZ 293787 B6 CZ293787 B6 CZ 293787B6 CZ 20014653 A CZ20014653 A CZ 20014653A CZ 20014653 A CZ20014653 A CZ 20014653A CZ 293787 B6 CZ293787 B6 CZ 293787B6
Authority
CZ
Czechia
Prior art keywords
amino acids
conjugates
amino acid
polymer
units
Prior art date
Application number
CZ20014653A
Other languages
Czech (cs)
English (en)
Other versions
CZ20014653A3 (cs
Inventor
Karel Doc. Ing. Drsc. Ulbrich
Tomáš Mgr. Etrych
Blanka Prof. Rndr. Drsc. Říhová
Markéta Mgr. Jelínková Phd.
Marek Mgr. Kovář
Original Assignee
Zentiva, A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, A.S. filed Critical Zentiva, A.S.
Priority to CZ20014653A priority Critical patent/CZ293787B6/cs
Priority to EP02805243A priority patent/EP1463529B9/en
Priority to SI200230855T priority patent/SI1463529T1/sl
Priority to KR10-2004-7009872A priority patent/KR20040076874A/ko
Priority to SK291-2004A priority patent/SK2912004A3/sk
Priority to AU2002366715A priority patent/AU2002366715A1/en
Priority to DE60233434T priority patent/DE60233434D1/de
Priority to JP2003554229A priority patent/JP4718117B2/ja
Priority to PCT/CZ2002/000070 priority patent/WO2003053473A2/en
Priority to EA200400802A priority patent/EA007353B1/ru
Priority to DK02805243.9T priority patent/DK1463529T5/da
Priority to CA002470976A priority patent/CA2470976A1/en
Priority to HU0500541A priority patent/HUP0500541A3/hu
Priority to AT02805243T priority patent/ATE439864T1/de
Priority to US10/499,422 priority patent/US7919076B2/en
Priority to ES02805243T priority patent/ES2331303T3/es
Priority to PL370719A priority patent/PL216518B1/pl
Priority to EP06025316A priority patent/EP1782833A3/en
Priority to PT02805243T priority patent/PT1463529E/pt
Publication of CZ20014653A3 publication Critical patent/CZ20014653A3/cs
Publication of CZ293787B6 publication Critical patent/CZ293787B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CZ20014653A 2001-12-20 2001-12-20 pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii CZ293787B6 (cs)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CZ20014653A CZ293787B6 (cs) 2001-12-20 2001-12-20 pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
EP02805243A EP1463529B9 (en) 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
SI200230855T SI1463529T1 (sl) 2001-12-20 2002-12-20 Za pH občutljivi polimerni konjugati antraciklinskega kancerostatičnega zdravila za ciljno terapijo
KR10-2004-7009872A KR20040076874A (ko) 2001-12-20 2002-12-20 표적 치료요법용 안트라사이클린 종양 정지 약물이 결합된피에이치-감응성 폴리머 결합체
SK291-2004A SK2912004A3 (en) 2001-12-20 2002-12-20 pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
AU2002366715A AU2002366715A1 (en) 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline drug
DE60233434T DE60233434D1 (de) 2001-12-20 2002-12-20 Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie
JP2003554229A JP4718117B2 (ja) 2001-12-20 2002-12-20 ターゲット療法用アントラサイクリン系制癌薬のｐＨ感受性重合体コンジュゲート
PCT/CZ2002/000070 WO2003053473A2 (en) 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline drug
EA200400802A EA007353B1 (ru) 2001-12-20 2002-12-20 pH-ЧУВСТВИТЕЛЬНЫЕ ПОЛИМЕРНЫЕ КОНЪЮГАТЫ АНТРАЦИКЛИНОВЫХ КАНЦЕРОСТАТИЧЕСКИХ АКТИВНЫХ АГЕНТОВ ДЛЯ ТЕРАПИИ НАПРАВЛЕННОГО ДЕЙСТВИЯ
DK02805243.9T DK1463529T5 (da) 2001-12-20 2002-12-20 PH-følsomme polymere konjugater af et cancerostatisk anthracyclinlægemiddel til målrettet terapi
CA002470976A CA2470976A1 (en) 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline drug
HU0500541A HUP0500541A3 (en) 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
AT02805243T ATE439864T1 (de) 2001-12-20 2002-12-20 Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie
US10/499,422 US7919076B2 (en) 2001-12-20 2002-12-20 PH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
ES02805243T ES2331303T3 (es) 2001-12-20 2002-12-20 Conjugados polimericos sensibles al ph de un farmaco cancerostatico de antraciclina para terapia dirigida.
PL370719A PL216518B1 (pl) 2001-12-20 2002-12-20 Polimerowe koniugaty leków przeciwnowotworowych i kompozycja farmaceutyczna
EP06025316A EP1782833A3 (en) 2001-12-20 2002-12-20 pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
PT02805243T PT1463529E (pt) 2001-12-20 2002-12-20 Conjugados poliméricos sensíveis ao ph de uma antraciclina citoestática para terapia-alvo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CZ20014653A CZ293787B6 (cs) 2001-12-20 2001-12-20 pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii

Publications (2)

Publication Number Publication Date
CZ20014653A3 CZ20014653A3 (cs) 2003-08-13
CZ293787B6 true CZ293787B6 (cs) 2004-07-14

Family

ID=5473644

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20014653A CZ293787B6 (cs) 2001-12-20 2001-12-20 pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii

Country Status (18)

Country Link
US (1) US7919076B2 (https=)
EP (2) EP1463529B9 (https=)
JP (1) JP4718117B2 (https=)
KR (1) KR20040076874A (https=)
AT (1) ATE439864T1 (https=)
AU (1) AU2002366715A1 (https=)
CA (1) CA2470976A1 (https=)
CZ (1) CZ293787B6 (https=)
DE (1) DE60233434D1 (https=)
DK (1) DK1463529T5 (https=)
EA (1) EA007353B1 (https=)
ES (1) ES2331303T3 (https=)
HU (1) HUP0500541A3 (https=)
PL (1) PL216518B1 (https=)
PT (1) PT1463529E (https=)
SI (1) SI1463529T1 (https=)
SK (1) SK2912004A3 (https=)
WO (1) WO2003053473A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297827B6 (cs) * 2005-09-05 2007-04-04 Zentiva, A. S. Zpusob prípravy polymerních konjugátu doxorubicinu s pH-rízeným uvolnováním léciva

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ294996B6 (cs) * 2003-07-16 2005-04-13 Ústav Makromolekulární Chemie Av Čr Reaktivní polymery a kopolymery na bázi N-(2-hydroxypropyl)methakrylamidu, způsob jejich přípravy a jejich použití pro syntézu polymerních léčiv, pro modifikaci biologicky aktivních proteinů a přípravu systémů pro dopravu genů
US7812051B2 (en) 2004-08-11 2010-10-12 Arqule, Inc. Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
CZ2006207A3 (cs) * 2006-03-28 2008-01-16 Zentiva, A. S. Micelární nosiče léčiv s protinádorovou aktivitou
CN101501492B (zh) 2006-08-09 2013-05-15 住友电木株式会社 糖链捕获物及其用途
CZ2006505A3 (cs) * 2006-08-09 2008-04-09 Zentiva, A. S. Polymerní konjugáty doxorubicinu s pH-rízeným uvolnováním léciva a zpusob jejich prípravy
CZ2006592A3 (cs) 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
EP2152686B1 (en) 2007-04-30 2014-12-17 ArQule, Inc. Hydroxy sulfonate of quinone compounds and their uses
CZ301288B6 (cs) * 2008-10-23 2009-12-30 Zentiva, A. S Polymerní prípravek se synergickým úcinkem pri lécbe nádorových onemocnení
CZ302830B6 (cs) * 2009-12-15 2011-11-30 Ústav makromolekulární chemie AV CR, v.v.i. Vysokomolekulární polymerní nosice léciv odvozené od dendrimeru a jejich konjugáty s lécivy pro lécbu zejména pevných nádoru
EP3069715A1 (en) 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
JP7390000B2 (ja) * 2016-10-14 2023-12-01 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 抗体－ポリマー－薬物コンジュゲート
JP2022529183A (ja) * 2019-04-17 2022-06-17 アヴィディア テクノロジーズ， インコーポレイテッド リガンド提示および／または薬物送達のためのスターポリマーを製造する組成物および方法
CZ309828B6 (cs) * 2019-10-09 2023-11-15 I.T.A.-Intertact S.R.O. Fluorescenční polymer, fluorescenční sonda a konjugační sada pro pokročilé funkční analýzy buněk v hematologii, imunologii a mikrobiologii, způsob jejich přípravy a jejich použití
CN114641316A (zh) * 2019-10-30 2022-06-17 Cis制药股份公司 用于递送活性剂的生物相容性聚合物药物载体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297827B6 (cs) * 2005-09-05 2007-04-04 Zentiva, A. S. Zpusob prípravy polymerních konjugátu doxorubicinu s pH-rízeným uvolnováním léciva

Also Published As

Publication number Publication date
EP1463529B1 (en) 2009-08-19
AU2002366715A8 (en) 2003-07-09
DK1463529T5 (da) 2011-06-27
DE60233434D1 (de) 2009-10-01
PT1463529E (pt) 2009-11-03
EP1463529B9 (en) 2011-03-23
HUP0500541A2 (hu) 2005-09-28
EA007353B1 (ru) 2006-10-27
ES2331303T9 (es) 2011-08-18
ES2331303T3 (es) 2009-12-29
CA2470976A1 (en) 2003-07-03
US20060057099A1 (en) 2006-03-16
ATE439864T1 (de) 2009-09-15
US7919076B2 (en) 2011-04-05
EP1782833A2 (en) 2007-05-09
AU2002366715A1 (en) 2003-07-09
WO2003053473A3 (en) 2004-04-29
HUP0500541A3 (en) 2011-08-29
PL216518B1 (pl) 2014-04-30
EP1782833A3 (en) 2008-03-19
SI1463529T1 (sl) 2010-01-29
SK2912004A3 (en) 2004-12-01
WO2003053473A2 (en) 2003-07-03
PL370719A1 (en) 2005-05-30
EA200400802A1 (ru) 2005-02-24
CZ20014653A3 (cs) 2003-08-13
JP4718117B2 (ja) 2011-07-06
EP1463529A2 (en) 2004-10-06
KR20040076874A (ko) 2004-09-03
DK1463529T3 (da) 2009-10-19
JP2005519044A (ja) 2005-06-30

Similar Documents

Publication Publication Date Title
Ulbrich et al. Antibody-targeted polymer–doxorubicin conjugates with pH-controlled activation
Etrych et al. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties
Ulbrich et al. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity
Etrych et al. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting
Li Poly (L-glutamic acid)–anticancer drug conjugates
US8603990B2 (en) Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation
Etrych et al. Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting
EP1463529B9 (en) Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
US20110014151A1 (en) Macromolecule conjugate
Etrych et al. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy
AU4094300A (en) Amplification of folate-mediated targeting to tumor cells using polymers
Etrych et al. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity
ES2717836T3 (es) Sistema de administración de fármacos multifuncional a base de ácido polimálico
JP5781084B2 (ja) 樹状高分子量ポリマー薬物担体および特に固形腫瘍の処置のための薬物とのそれらの結合体
Pechar et al. Poly (ethylene glycol)-doxorubicin conjugates with pH-controlled activation
Chytil et al. Structural design and synthesis of polymer prodrugs
CZ2003605A3 (en) pH sensitive polymeric conjugates of anthracycline cancerostatic for targeted therapy
Etrych et al. Micellar and Antibody‐Targeted Polymer Therapeutics
SK9785A3 (en) Polymeric remedy and preparation method thereof
Rihova et al. HPMA-Anticancer Drug Conjugates
Ulbrich et al. Synthetic polymer-drug conjugates for human therapy
DUNCAN Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Cardiff, UK

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20211220